Abstract:The PI3K/AKT/mTOR signalling pathway is one of the most frequently activated pathways in breast cancer and also plays a central role in the regulation of several physiologic functions. There are major efforts ongoing to exploit precision medicine by developing inhibitors that target the three kinases (PI3K, AKT, and mTOR). Although multiple compounds have been developed, at present, there are just three inhibitors approved to target this pathway in patients with advanced ER-positive, HER2-negative breast cancer: everolimus (mTOR inhibitor), alpelisib (PIK3CA inhibitor), and capivasertib (AKT inhibitor). Like most targeted cancer drugs, resistance poses a major problem in the clinical setting and is a factor that has frequently limited the overall efficacy of these agents. Drug resistance can be categorised into intrinsic or acquired resistance depending on the timeframe it has developed within. Whereas intrinsic resistance exists prior to a specific treatment, acquired resistance is induced by a therapy. The majority of patients with ER-positive, HER2-negative advanced breast cancer will likely be offered an inhibitor of the PI3K/AKT/mTOR pathway at some point in their cancer journey, with the options available depending on the approval criteria in place and the cancer's mutation status. Within this large cohort of patients, it is likely that most will develop resistance at some point, which makes this an area of interest and an unmet need at present. Herein, we review the common mechanisms of resistance to agents that target the PI3K/AKT/mTOR signalling pathway, elaborate on current management approaches, and discuss ongoing clinical trials attempting to mitigate this significant issue. We highlight the need for additional studies into AKT1 inhibitor resistance in particular.

Lessons to Learn for Adequate Targeted Therapy Development in Metastatic Colorectal Cancer Patients

Chemoresistant Colorectal Cancer Cells, the Cancer Stem Cell Phenotype, and Increased Sensitivity to Insulin-like Growth Factor-I Receptor Inhibition

Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies

Progress and Challenge in Development of Biotherapeutics Targeting MET Receptor for Treatment of Advanced Cancer.

Role of HGF–MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer

Resistance to Targeted Inhibitors of the PI3K/AKT/mTOR Pathway in Advanced Oestrogen-Receptor-Positive Breast Cancer

Manipulating the tumor immune microenvironment to improve cancer immunotherapy: IGF1R, a promising target

Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement

Epidermal growth factor receptor inhibitors in oncology

Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer

Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer

Impact on Cancer Hallmarks and Therapeutic Approaches

Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance

Adaptive Resistance to Targeted Therapies in Cancer.

Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer

Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer

The Future of ER+/HER2− Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors

EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance

Emerging Intrinsic Therapeutic Targets for Metastatic Breast Cancer

Molecular and Clinical Determinants of Acquired Resistance and Treatment Duration for Targeted Therapies in Colorectal Cancer

The MET Oncogene: An Update on Targeting Strategies